Our Mission and Vision
At Ansa Biotechnologies, we’ve established a new way to manufacture synthetic DNA that overcomes the limitations of traditional DNA synthesis methods. We envision a future where our technology empowers scientists to develop solutions for the world’s biggest problems in health and sustainability.
Milestones
Publication: De novo DNA synthesis using polymerase-nucleotide conjugates in Nature Biotechnology
Pre-seed round led by 50 Years
Seed round led by Horizon Ventures
First 50mer synthesis with 99.5%+ stepwise yield
Series A round led by Northpond Ventures
First 1005mer synthesis: complex sequence with 99.9% stepwise yield
Early Access Program of 600 bp first customer ship
Commercial availability of Ansa DNA Fragments and Ansa Clonal DNA products ≤ 600 bp
Commercial availability of Ansa Clonal DNA ≤ 5 kb
Commercial availability of Ansa Clonal DNA ≤ 7.5 kb
Early Access program of Clonal DNA up to 50 kb
Series B round led by Cerberus Ventures
Commercial availability of XL Clonal DNA up to 50 kb
Partnership with Integrated DNA Technologies (IDT) Announced
